Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

To the editor: Infusion-related reactions (IRRs) occur commonly with rituximab administration, a type-I anti-CD20 monoclonal antibody that is routinely used in the treatment of chronic lymphocytic leukemia (CLL).[1][1],[2][2] The pathophysiology of these reactions has been attributed to cytokine

[1]  M. Hallek.  Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment , 2015, American journal of hematology.

[2]  C. Fegan,et al.  Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study , 2015, Leukemia.

[3]  G. Fingerle-Rowson,et al.  Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset , 2014 .

[4]  R. Bouabdallah,et al.  Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. , 2014, Blood.

[5]  Michael Hallek,et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.

[6]  Ping Wang,et al.  Tocilizumab Overcomes Chemo-Resistance Of CLL Cells , 2013 .

[7]  C. Klein,et al.  Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. , 2013, Blood.

[8]  C. Klein,et al.  Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. , 2013, Leukemia research.

[9]  T. Egberts,et al.  Rituximab‐induced thrombocytopenia: a cohort study , 2012, European journal of haematology.

[10]  R. Gascoyne,et al.  A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. , 2012, Blood.

[11]  S. Rose-John,et al.  Interleukin-6 in sepsis and capillary leakage syndrome. , 2012, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[12]  Miho Suzuki,et al.  IL-6/IL-6 receptor system and its role in physiological and pathological conditions. , 2012, Clinical science.

[13]  C. Klein,et al.  Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells , 2011, British journal of haematology.

[14]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[15]  O. Shpilberg,et al.  Rituximab‐associated acute thrombocytopenia: An under‐diagnosed phenomenon , 2009, American journal of hematology.

[16]  I. O. Kara,et al.  Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: Correlation with disease stage and prognosis , 2007, Advances in therapy.

[17]  R. Andersson,et al.  Modulation of Cytokine-Induced Production of IL-8 in Vitro by Interferons and Glucocorticosteroids , 2004, Inflammation.

[18]  J. Rossi,et al.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  M. Grever,et al.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  V. Diehl,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .

[21]  J. Byrd,et al.  Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Gamble,et al.  Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Nemunaitis,et al.  A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. , 1995, Blood.

[24]  A. Philippon,et al.  REFERENCES CONTENT ALERTS Updated information and services can be found at: , 1999 .

[25]  M. Baggiolini,et al.  [Ca2+]i Changes and Respiratory Burst in Human Neutrophils and Monocytes Induced by NAP‐1/Interleukin‐8, NAP‐2, and gro/MGSA , 1991, Journal of leukocyte biology.